(Reuters) - Mylan NV, which has come under fire for its drug pricing, said on Friday it would start selling a generic version of its life-saving EpiPen allergy treatment for $300 per two-pack, a more ...

Drugmaker Mylan has started selling a generic version of its emergency allergy treatment EpiPen at half the price of the branded option, the cost of which drew national scorn and attracted ...

Teva Pharmaceutical says rival generic drugmaker Mylan is engaging in a “desperate attempt” to keep its board and shareholders from considering Teva’s $40 billion-plus takeover offer. The claim, ...

Shares of much-maligned drugmaker Mylan NV MYL climbed on Thursday after the U.S. Justice Department announced that it officially reached a settlement with the company regarding its EpiPen lawsuit.

*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Updated at 12:40 p.m. WASHINGTON • U.S. Sens. Richard Blumenthal, Charles Grassley and Amy Klobuchar asked the Justice Department ...

Mylan NV said on Thursday, Aug. 25, it would reduce the out-of-pocket cost of its severe allergy treatment EpiPen through a discount program, a day after Democratic Presidential candidate Hillary ...

(Reuters) - U.S. regulators said on Wednesday that Mylan NV's EpiPen products are in shortage due to manufacturing delays that are creating intermittent supply constraints of the emergency allergy ...

Mylan N.V. (NASDAQ, TASE: MYL) today announced that its abbreviated new drug application (ANDA) for fluticasone propionate 100, 250, 500 mcg and salmeterol 50 mcg inhalation powder has been accepted ...

The drug company that makes the EpiPen says it isn't nearly as profitable as many people assume it is. At least that's the message Mylan NV CEO Heather Bresch will try to deliver to members of ...

Sweetening cash offer for Perrigo could hurt Mylan's overall finances. Moody’s Investors Service affirmed the Baa3 senior unsecured rating of Mylan Inc., but changed the outlook for the generic drug ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. So what: According ...

Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36 mg and 54 mg, a generic version of Janssen's Concerta® ...